Peroxisome proliferator-activated receptor agonists (PPARs): A promising prospect in the treatment of psoriasis and psoriatic arthritis;Os receptores ativados pelo proliferador de peroxissoma (PPAR): Uma perspectiva promissora na condução da psoríase e artrite psoriásica

Anais Brasileiros de Dermatologia

Volumn 88, Issue 6, 2013, Pages 1029-1035

  Lima, Emerson de Andrade ^a   de Andrade Lima, Mariana Modesto Dantas ^b   Marques, Cláudia Diniz Lopes ^b   Pinto Duarte, Angela Luzia Branco ^b   Pita, Ivan da Rocha ^b   Pita, Maira Galdino da Rocha ^b  

^a Recife Santa Casa de Misericórdia Hospital   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Arthritis; PPAR alpha; Psoriasis; Psoriatic

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL) ETHOXY] PHENYL] ETHYLAMINO] BENZOIC ACID METHYL ESTER; 2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL) UREIDO] ETHYL] PHENYLTHIO] 2 METHYLPROPIONIC ACID; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY) PROPOXY] PHENOXY] ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO] PHENOXY] ACETIC ACID; CIGLITAZONE; CLOFIBRATE; CYTOKINE; FARGLITAZAR; FENOFIBRATE; GEMFIBROZIL; LIGAND; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PIRINIXIC ACID; RAGAGLITAZAR; ROSIGLITAZONE; TESAGLITAZAR; TROGLITAZONE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERTENSION; INCIDENCE; INFLAMMATION; INNATE IMMUNITY; KERATINOCYTE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PSORIASIS; PSORIATIC ARTHRITIS; RISK;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, PSORIATIC; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; METABOLIC SYNDROME X; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PSORIASIS;

EID: 84893080225     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/abd1806-4841.20132653     Document Type: Article

References (62)

1. Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167:717-24.
2. Queiro R, Alperi M, Alonso-Castro S, Ballina J, Huergo-Zapico L, Fernández-Guizán A, et al. Patients with psoriatic arthritis may show differences in their clinical and genetic profiles depending on their age at psoriasis onset. Clin Exp Rheumatol. 2012;30:476-80.
3. Mease PJ. Psoriatic arthritis assessment and treatment update. Curr Opin Rheumatol. 2009;21:348-55.
4. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Semin Arthritis Rheum. 2004;34:585-92.
5. Hueber AJ, McInnes IB. Immune regulation in psoriasis and psoriatic arthritis--recent developments. Immunol Lett. 2007;114:59-65.
6. Ghoreschi K, Weigert C, Röcken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol. 2007;25:574-80.
7. Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203:2577-87.
8. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199:125-30.
9. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429-42.
10. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233-40.
11. Hvid H, Teige I, Kvist PH, Svensson L, Kemp K. TPA induction leads to a Th17-like response in transgenic K14/VEGF mice: a novel in vivo screening model of psoriasis. Int Immunol. 2008;20:1097-106.
12. Ghoreschi K, Röcken M. Molecular and cellular basis for designing gene vaccines against inflammatory autoimmune disease. Trends Mol Med. 2003;9:331-8.
13. Alwawi EA, Krulig E, Gordon KB. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther. 2009;22:431-40.
14. Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol. 2008;58:443-6.
15. Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomized double blind multicentre trial. BMJ. 2010;340:c147.
16. Tak PP, Kalden JR. Advances in rheumatology: new targeted-therapeutics. Arthritis Res Ther. 2011;13:S5.
17. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52:722-32.
18. Cohen SN, Baron SE, Archer CB; British Association of Dermatologists and Royal College of General Practitioners. Guidance on the diagnosis and clinical management of psoriasis. Clin Exp Dermatol. 2012;37:13-8.
19. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298:321-8.
20. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology. 2008;216:152-5.
21. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263-71.
22. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17:4-12.
23. van Dielen FM, Buurman WA, Hadfoune M, Nijhuis J, Greve JW. Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. J Clin Endocrinol Metab. 2004;89:4062-8.
24. Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab. 2012;23:351-63.
25. Na HK, Surh YJ. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation. Biochem Pharmacol. 2003;66:1381-91.
26. Tavares V, Hirata MH, Hirata RD. Peroxisome proliferator-activated receptor gamma (PPARgamma): molecular study in glucose homeostasis, lipid metabolism and therapeutic approach. Arq Bras Endocrinol Metabol. 2007;51:526-33.
27. Castrillo A, Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol. 2004;20:455-80.
28. Pyper SR, Viswakarma N, Yu S, Reddy JK. PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal. 2010;8:e002.
29. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature. 2008;454:470-7.
30. Wang WM, Zhang HD, Jin YM, Zhu BB, Chen N. PPAR-gamma agonists inhibit TGFbeta1-induced chemokine expression in human tubular epithelial cells. Acta Pharmacol Sin. 2009;30:107-12
31. Lee JW, Bajwa PJ, Carson MJ, Jeske DR, Cong Y, Elson CO, et al. Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice. Gastroenterology. 2007;133:108-23.
32. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 2007;28:551-8.
33. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum. 1998;41:1103-10.
34. Bojic LA, Sawyez CG, Telford DE, Edwards JY, Hegele RA, Huff MW. Activation of peroxisome proliferator-activated receptor delta inhibits human macrophage foam cell formation and the inflammatory response induced by very low-density lipoprotein. Arterioscler Thromb Vasc Biol. 2012;32:2919-28.
35. Ohshima K, Mogi M, Horiuchi M. Role of Peroxisome Proliferator-Activated Receptorgamma in Vascular Inflammation. Int J Vasc Med. 2012;2012:508416.
36. Palma A, Sainaghi PP, Amoruso A, Fresu LG, Avanzi G, Pirisi M, et al. Peroxisome proliferator-activated receptor-gamma expression in monocytes/macrophages from rheumatoid arthritis patients: relation to disease activity and therapy efficacy-a pilot study. Rheumatology (Oxford). 2012;51:1942-52
37. Shirinsky IV, Shirinsky VS. Targeting Nuclear Hormone Receptors: PPARalpha Agonists as Potential Disease-Modifying Drugs for Rheumatoid Arthritis. Int J Rheumatol. 2011;2011:937843.
38. Celinski K, Dworzanski T, Fornal R, Korolczuk A, Madro A, Slomka M. Comparison of the anti-inflammatory and therapeutic actions of PPAR-gamma agonists rosiglitazone and troglitazone in experimental colitis. J Physiol Pharmacol. 2012;63:631-40.
39. Annese V, Rogai F, Settesoldi A, Bagnoli S. PPARgamma in Inflammatory Bowel Disease. PPAR Res. 2012;2012:620839.
40. Murata T, He S, Hangai M, Ishibashi T, Xi XP, Kim S, et al. Peroxisome proliferatoractivated receptor-gamma ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41:2309-17.
41. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-6.
42. Goetze S, Xi XP, Kawano H, Gotlibowski T, Fleck E, Hsueh WA, et al. PPAR gammaligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol. 1999;33:798-806.
43. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat. 2008;19:5-21.
44. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860-7.
45. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821-30.
46. Fresno M, Alvarez R, Cuesta N. Toll-like receptors, inflammation, metabolism and obesity. Arch Physiol Biochem. 2011;117:151-64.
47. Yessoufou A, Atègbo JM, Attakpa E, Hichami A, Moutairou K, Dramane KL, et al. Peroxisome proliferator-activated receptor-alpha modulates insulin gene transcription factors and inflammation in adipose tissues in mice. Mol Cell Biochem. 2009;323:101-11.
48. Wu D, Molofsky AB, Liang HE, Ricardo-Gonzalez RR, Jouihan HA, Bando JK, et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science. 2011;332:243-7.
49. Taguchi K, Okada A, Yasui T, Kobayashi T, Ando R, Tozawa K, et al. Pioglitazone, a peroxisome proliferator activated receptor gamma agonist, decreases renal crystal deposition, oxidative stress and inflammation in hyperoxaluric rats. J Urol. 2012;188:1002-11.
50. Olson EJ, Pearce GL, Jones NP, Sprecher DL. Lipid effects of peroxisome proliferator-activated receptor-delta agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Arterioscler Thromb Vasc Biol. 2012;32:2289-94.
51. Liu SN, Liu Q, Li LY, Huan Y, Sun SJ, Shen ZF. Long-term fenofibrate treatment impaired glucose-stimulated insulin secretion and up-regulated pancreatic NF-kappa B and iNOS expression in monosodium glutamate-induced obese rats: is that a latent disadvantage? J Transl Med. 2011;9:176.
52. Kraja AT, Province MA, Straka RJ, Ordovas JM, Borecki IB, Arnett DK. Fenofibrate and metabolic syndrome. Endocr Metab Immune Disord Drug Targets. 2010;10:138-48.
53. Li FY, Lam KS, Xu A. Therapeutic perspectives for adiponectin: an update. Curr Med Chem. 2012;19:5513-23.
54. Kuenzli S, Saurat JH. Peroxisome proliferator-activated receptors in cutaneous biology. Br J Dermatol. 2003;149:229-36.
55. Ellis CN, Varani J, Fisher GJ, Zeigler ME, Pershadsingh HA, Benson SC, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol. 2000;136:609-16.
56. Hanley K, Kömüves LG, Bass NM, He SS, Jiang Y, Crumrine D, et al. Fetal epidermal differentiation and barrier development in vivo is accelerated by nuclear hormone receptor activators. J Invest Dermatol. 1999;113:788-95.
57. Kömüves LG, Hanley K, Man MQ, Elias PM, Williams ML, Feingold KR. Keratinocyte differentiation in hyperproliferative epidermis: topical application of PPARalpha activators restores tissue homeostasis. J Invest Dermatol. 2000;115:361-7.
58. Hanley K, Jiang Y, He SS, Friedman M, Elias PM, Bikle DD, et al. Keratinocyte differentiation is stimulated by activators of the nuclear hormone receptor PPARalpha. J Invest Dermatol. 1998;110:368-75.
59. Pershadsingh HA, Sproul JA, Benjamin E, Finnegan J, Amin NM. Treatment of psoriasis with troglitazone therapy. Arch Dermatol. 1998;134:1304-5.
60. Bongartz T, Coras B, Vogt T, Schölmerich J, Müller-Ladner U. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology (Oxford). 2005;44:126-9.
61. Robertshaw H, Friedmann PS. Pioglitazone: a promising therapy for psoriasis. Br J Dermatol. 2005;152:189-91.
62. Lima Ede A, Lima Mde A. Reviewing concepts in the immunopathogenesis of psoriasis. An Bras Dermatol. 2011;86:1151-8.